Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Evidence-Based Management of Adult Atopic Dermatitis: Comorbidities, Food Allergy, and Guideline-Based Therapies
Description
The talk reviewed evidence-based management of adult atopic dermatitis, emphasizing how current AAD and AAAAI/Quad AI guidelines both overlap and differ because they weigh evidence and patient input differently. It highlighted that adult AD is associated with many comorbidities, including mental health conditions, other atopic diseases, infections, osteoporosis, and possibly cardiometabolic disorders, but screening guidance remains limited and better studies are needed to determine whether early detection changes outcomes. In discussing food allergy, the speaker strongly cautioned against routine broad IgE, RAST, or skin prick testing in AD because false positives are common, especially in children; testing should be reserved for patients with convincing immediate symptoms or a clear history suggesting food-related flares, ideally using food diaries and targeted allergist-guided evaluation. For treatment, bathing and wet wraps were supported, with daily bathing considered safe and pre-hydration/moisturizing after bathing encouraged. Strong evidence supported newer topical non-steroidal prescription therapies, while antimicrobials, topical antihistamines, and prescription moisturizers had weak or negative support; topical JAK inhibitors were effective but faced patient concern because of boxed warnings. For moderate to severe disease, biologics and JAK inhibitors all had strong evidence, while systemic steroids and older immunosuppressants were discouraged or only conditionally recommended. Comparative evidence suggested topical therapies are broadly effective but hard to rank, whereas systemic JAK inhibitors act fastest and, at higher doses, tend to be the most effective overall, with biologics effective but generally slower. The speaker also noted that bleach baths appear to offer at most modest benefit over tap water baths, and dietary avoidance should be individualized because some patients do report food-related worsening, though routine restriction can be harmful and may increase allergy risk.
View moreConclusions
- Atopic dermatitis is associated with numerous adult comorbidities, but current evidence is not strong enough to support routine screening recommendations or prove that screening improves outcomes.
- Food allergy testing should not be used routinely in atopic dermatitis because IgE, RAST, and skin prick tests produce many false positives in this population.
- Food allergy evaluation is most appropriate when there are true food allergy symptoms, immediate reactions after specific foods, or a clear pattern of eczema worsening with exposures.
- Empiric elimination diets are generally discouraged because unnecessary food avoidance can worsen nutrition and may actually increase the risk of true food allergy.
- Daily bathing is safe for atopic dermatitis and should not be discouraged, even though the optimal bathing frequency is still unclear.
- Pre-hydration or soak-and-seal care after bathing appears helpful and is a reasonable practical strategy for many patients.
- Topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and topical JAK inhibitors have evidence of benefit, but topical antimicrobials, antiseptics, and topical antihistamines are generally not recommended.
- Moderate-to-severe atopic dermatitis should be escalated to effective systemic options rather than relying on repeated systemic corticosteroids.
- Among currently available systemic therapies, JAK inhibitors tend to produce the fastest and strongest short-term responses, while biologics are effective but generally slower.
- Upadacitinib appears to be the most efficacious systemic option overall, with abrocitinib and some other JAK inhibitors close behind and dupilumab/tralokinumab/lebrikizumab somewhat lower in comparative rankings.
- Bleach baths may provide only modest benefit compared with plain water baths, so they are low-risk adjuncts rather than high-impact treatments.
- Current guidelines still leave major gaps around phenotype-specific management, comorbidity-driven treatment selection, and sequencing after treatment failure.
- Treatment decisions in atopic dermatitis are increasingly shaped not only by efficacy data but also by patient preferences, cost, access, and concerns about safety warnings.
- AAAAI/ACAAI atopic dermatitis guideline panel. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024 Mar;132(3):274-312.
- Davis et al. Update to AAD guidelines on AD comorbidities. Journal of the American Academy of Dermatology. DOI cited on slide.
- Wollenberg et al.
- Sidbury et al.
- Davis et al. American Academy of Dermatology guideline update for atopic dermatitis. Journal of the American Academy of Dermatology.#10.1016/s0190-9622(96)90486-7
- Chu et al. Systematic review of 219 trials of 68 interventions for AAAAI guidelines. Journal of Allergy and Clinical Immunology. 2023.
- Silverberg et al. Updated network meta-analysis of systemic therapies for atopic dermatitis. Dermatol Ther (Heidelb). 2023.
- Hua et al. Whether daily bathing or showering worsens atopic dermatitis severity. Archives of Dermatologic Research. 2021.
- Hon et al. Bleach baths in atopic dermatitis. Journal of Dermatological Treatment. 2016.